IL-12 augments adoptive cell therapy by reshaping CD8+ T dynamics and broadening antitumor immunity
Cancer Letters · 2026
DOI: 10.1016/j.canlet.2026.218563 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2026. Verfasst von Yue Huang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Sheng Yushou Center of Cell Biology and Immunology, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, 200240, China…. Hauptthemen laut MEDLINE: Interleukin-12, CD8-Positive T-Lymphocytes, Immunotherapy, Adoptive, Neoplasms. Die Arbeit nennt 57 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Adoptive cell therapy (ACT) against solid tumors is constrained by tumor heterogeneity, immunosuppressive microenvironments, and insufficient T cell potency and persistence. Although IL-12 has long been recognized as a potent enhancer of T-cell immunity, its clinical application has been hindered by systemic toxicity and the lack of a strategy to harness its benefits without chronic exposure. Here, we show that ex vivo IL-12 preconditioning programs tumor-specific T cells with increased antigen sensitivity, yielding superior antitumor activity compared with IL-7/IL-15. Systemic delivery of Pro-IL-12 further rejuvenates exhausted CD8+ tumor-infiltrating lymphocytes (TILs) by restoring IL-2 hypersensitivity, sustaining persistence, and strengthening effector machinery. When combined with ACT, a single dose of Pro-IL-12 reinstated IFN-γ production in exhausted TILs and doubled intratumoral T-cell accumulation via upregulation of IL-2Rα and increased IL-2 sensitivity. Pro-IL-12 markedly improved therapeutic outcomes, inducing durable complete tumor regression, promoting antigen spreading, and establishing long-term immune memory that prevented relapse from antigen-loss tumor. Across multiple xenograft models, including pancreatic cancer, lymphoma and triple negative breast cancer, distinct human CAR-T products paired with Pro-IL-12 enhanced tumor eradication without cytokine release syndrome. Together, these findings establish precision delivery of IL-12 as a translatable strategy that harnesses known IL-12 biology to achieve robust antitumor efficacy without systemic toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Sheng Yushou Center of Cell Biology and Immunology, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, 200240, China; Changping Laboratory, Beijing, 102206, China.
- Changping Laboratory, Beijing, 102206, China; Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing, China.
- Changping Laboratory, Beijing, 102206, China.
- Sheng Yushou Center of Cell Biology and Immunology, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, 200240, China.
- Changping Laboratory, Beijing, 102206, China; Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing, China. Electronic address: yangxinfu@mail.tsinghua.edu.cn.
- Sheng Yushou Center of Cell Biology and Immunology, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, 200240, China. Electronic address: xuanmingyang@sjtu.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Huang, Y., Liu, X., Chen, Y., Zhang, H., Zhang, J., Fu, Y. X., Yang, X., & Yang, Z. (2026). IL-12 augments adoptive cell therapy by reshaping CD8+ T dynamics and broadening antitumor immunity. Cancer Letters. https://doi.org/10.1016/j.canlet.2026.218563
Vancouver
Huang Y, Liu X, Chen Y, Zhang H, Zhang J, Fu YX, et al. IL-12 augments adoptive cell therapy by reshaping CD8+ T dynamics and broadening antitumor immunity. Cancer Letters. 2026. doi:10.1016/j.canlet.2026.218563
BibTeX
@article{Huang2026,
author = {Huang, Yue and Liu, Xiangming and Chen, Yiwei and Zhang, Huihui and Zhang, Junshi and Fu, Yang-Xin and Yang, Xuanming and Yang, Zaopeng},
title = {IL-12 augments adoptive cell therapy by reshaping CD8+ T dynamics and broadening antitumor immunity},
journal = {Cancer Letters},
year = {2026},
doi = {10.1016/j.canlet.2026.218563}
}
EUVIMED